We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Methods Evaluated for Autoimmune Hemolytic Anemia Diagnosis

By LabMedica International staff writers
Posted on 21 Jun 2012
The use of both the gel test (GT) and flow cytometry (FC) techniques in the detection of red blood cell-bound immunoglobulin G (IgG) has been assessed. More...


The two tests are important in the diagnosis of autoimmune hemolytic anemia (AIHA) in cases that were negative by the conventional tube technique (CTT) or direct antiglobulin test (DAT).

Hematologists at Ain Shams University (Cairo, Egypt) conducted a case-control study between August 2008 and October 2010. The study included 50 patients, who were clinically diagnosed to have Warm Antibody AIHA with negative CTT-DAT. Fifty-five healthy volunteers with negative polyspecific CTT-DAT were also enrolled as control subjects.

Blood samples were tested by the Direct Antiglobulin Test by CTT and GT and by FC technique. In the FC assay, the results were expressed as percent fluorescence, which is the percentage of erythrocytes expressing the anti-human IgG at levels above those of the isotype control, and mean fluorescence intensity (MFI). For the GT assay, a positive test is where agglutinated cells formed a red line on gel surface or dispersed agglutinates in the gel and were graded from G1-G4. For the CTT, agglutination was detected macroscopically and confirmed by microscopic examination.

The results of the study showed that 46 of 50 (92%) patients were positive by GT. The Receiver Operating Characteristic curve for FC assay determined that a cut-off of 17.5% fluorescence was the best value for interpreting FC-DAT positively in the group of patients with hemolytic anemia, with 100% sensitivity and specificity. The best cut-off for MFI was 1.74, with 76% specificity and 96% sensitivity. Both mean percent fluorescence and MFI were significantly higher among patients when compared to controls. The FC assay was performed using the Coulter Epics XL 3-colour flow cytometer (Beckman Coulter Inc., Brea, CA, USA).

The authors concluded that GT and FC are sensitive tools for assessing CTT-DAT-negative AIHA. However, FC is more precise and so should be utilized when a strong clinical suspicion of AIHA is associated with dissonant CTT and GT results. They propose that FC percent fluorescence cut-off values should be employed to determine the Coombs’ negative AIHA cases. However, they do imply that larger studies are needed to define the best cut-off value for FC IgG DAT positivity in such cases. The study was published in the June 2012 issue of the International Journal of Laboratory Hematology.

Related Links:

Ain Shams University
Beckman Coulter Inc.



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.